Table 1.
FDA‐approved drugs and those in current clinical trials for treatment of anterior segment diseases
| Name and company | Drug delivery platform | Drug and excipients | Indications | Status |
|---|---|---|---|---|
| Acuvail™ (Allergan) | Eye drops | Solution of ketorolac tromethamine (0.45%) in carboxymethylcellulose (pH 6.8) | Reduction of pain and inflammation post cataract surgery | Approved |
| Azasite® (InSite Vision) | Eye drops | Solution of azithromycin (1.0%) in polycarbophil (Durasite®) | Bacterial conjunctivitis | Approved |
| Azasite Plus™ (InSite Vision) | Eye drops | Solution of azithromycin (1.0%)/dexamethasone (0.1%) (ISV‐502) in Durasite® | Blepharoconjunctivitis | Phase III completed |
| Bromsite™ (InSite Vision) | Eye drops | Solution of bromfenac sodium (0.075%) | Reduction of pain and inflammation post cataract surgery | Approved |
| Betoptic‐S™ (Alcon) | Eye drops | Suspension of betaxolol (0.25%) in polystyrene‐divinylbenzene) sulfonic acid, carbomer and BAC (0.01%) | Open angle glaucoma | Approved |
| Cationorm® (Santen Pharma) | Eye drops | Cationic emulsion | Dry eye | Approved |
| DexaSite™ (InSite Vision) | Eye drops | Solution of dexamethasone (0.1%) (ISV‐305) in Durasite® | Reduction of pain and inflammation post cataract surgery; and non‐bacterial blepharitis | Phase III |
| Durezol™ (Alcon) | Eye drops | Emulsion of difluprednate (0.05%) in castor oil, glycerine, boric acid, polysorbate 80 and sorbic acid (0.1%) | Anterior uveitis | Approved |
| EGP‐437 (Eyegate Pharma) | Iontophoresis | Solution of dexamethasone phosphate in EyeGate® II Drug Delivery System (EGDS) | Anterior uveitis | Phase III |
| Indocollirio® (Bausch & Lomb) | Eye drops | Suspension of indomethacin (0.1%) and hydroxypropyl‐b‐cyclodextrin (IND‐CD) | Mydriasis during cataract surgery or conjunctivitis | Approved |
| Lacrisert® (Aton Pharma) | Ocular insert | Sterile, rod‐shaped HPMC insert | Dry eye | Approved |
| Lumigan® (Allergan) | Eye drops | Solution of bimatoprost (0.03%) in BAC (0.005%) | Glaucoma | Approved |
| Mydriasert (Thea Pharma) | Ocular insert | Tropricamide (0.28 mg) and phenylephrine hydrochloride (5.4 mg) in ammoniomethacrylate copolymer, glycerol and ethylcellulose | Induced pre‐operative mydriasis | Approved |
| Ocusert® (Alza) | Ocular insert | Pilocarpine with EVA and alginic acid | Glaucoma | Approved |
| Prolensa™ (Bausch & Lomb) | Eye drops | Solution of bromfenac (0.07%) | Postoperative inflammation | Approved |
| Propine™ (Allergan) | Eye drops | Solution of dipivefrin‐HCl (0.1%) with BAC (0.02%) | IOP control in open angle glaucoma | Approved |
| Restasis™ (Allergan) | Eye drops | Cationic emulsion of cyclosporine (0.05%) in castor oil, glycerine, polysorbate 80 and carbomer | Dry eye | Approved |
| TobraDex® (Alcon) | Eye drops | Suspension of tobramycin/dexamethasone in xanthan gum | Blepharitis | Approved |
| Timoptic‐XE™ (Aton Pharma) | Eye drops | In situ gel solution of timolol maleate (0.25 or 0.5%) in gellan gum, mannitol, tromethamine and BAC (0.012%) | Glaucoma | Approved |
| Travatan™ (Alcon) | Eye drops | Solution of travaprost (0.004%) in BAC (0.015%) | Glaucoma | Approved |
| Xalatan™ (Pfizer) | Eye drops | Solution of latanoprost (0.005%) in BAC (0.015%) | Glaucoma | Approved |
| Zirgan™ (Bausch & Lomb) | Ophthalmic gel | Ophthalmic gel with ganciclovir (0.15%) with carbopol and BAC (0.0075%) | Acute herpetic keratitis | Approved |
All drug therapies mentioned above were also cross‐checked with www.clinicaltrials.gov.uk and its official company site. BAC, benzalkonim chloride; HPMC, hydroxypropylmethylcellulose.